Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth

Edwards Lifesciences said its transcatheter mitral and tricuspid therapies (TMTT) should generate about $250 million of 2026 revenue, up roughly 40% year over year, while maintaining a long-term target of approximately 10% annual revenue growth. A new CMS coverage policy could expand TAVR access by enabling single-operator procedures, removing hospital volume minimums and potentially supporting 100-200 new TAVR centers; management estimates simple-case capacity could rise 20%-40% over time. Key catalysts include PROGRESS trial data in about six weeks, expected PASCAL tricuspid approval before year-end, and expanding SAPIEN M3 and EVOQUE adoption, although management cautioned that physician uptake and new-center openings will take time. Edwards has repurchased more than $500 million of stock year to date, but 15 analysts have lowered near-term earnings estimates.

Analysis

The CMS change is more valuable as a utilization unlock than as a near-term new-center story. Lower-complexity cases can migrate to community programs, but the limiting input becomes proctoring, imaging workflow and trained operators; this favors EW's entrenched training infrastructure and installed-base economics over a smaller competitor's ability to simply sell a device. The likely 6-18 month effect is higher procedure throughput and pull-through demand for EW's broader structural-heart portfolio, while Abbott (ABT) and Medtronic (MDT) face greater pressure to match clinical-support intensity rather than merely price.

The next six weeks are a valuation-critical binary event, not a clean fundamental rerating. At a premium earnings multiple and with downward estimate revisions already underway, a merely statistically positive PROGRESS outcome may not be enough: investors will require a clinically persuasive endpoint, manageable procedural risk, and a credible regulatory/reimbursement path for earlier intervention. A miss, an ambiguous subgroup result, or evidence that medical management remains competitive would expose EW to multiple compression well before any benefit from CMS-enabled capacity reaches reported revenue.

Consensus may be over-crediting the addressable-market rhetoric and under-crediting adoption friction in mitral/tricuspid disease. These therapies require case selection, multidisciplinary referral patterns and hospital economic acceptance, so rapid revenue extrapolation from early launches is hazardous; however, EW's multi-platform strategy has a non-obvious advantage because it can preserve physician relationships even when a patient is unsuitable for any single modality. The investable inflection is therefore not the size of the theoretical market, but evidence over the next 1-3 quarters that new centers and existing accounts are increasing treated-patient flow without diluting procedure quality or gross margin.

Key Decisions for Investors

• Maintain a modest long EW / short MDT pair through the late-October PROGRESS readout, sized at 50-75 bps gross per leg. The pair isolates EW's structural-heart execution and clinical-positioning advantage from broad MedTech multiple risk; exit if PROGRESS misses its primary endpoint or if EW guides 2027 TAVR growth below mid-single digits.
• Do not add outright EW exposure ahead of data at the current premium valuation; use a post-results alert instead. Add on a 5-8% event-driven selloff only if trial data are clinically supportive and management can quantify a credible FDA/CMS pathway, targeting recovery toward the prior valuation range over 3-6 months; invalidation is a downward EPS-guide revision or weaker TMTT growth.
• For holders requiring event protection, buy 1-2 month EW put spreads spanning the TCT readout rather than selling volatility outright. The downside scenario is asymmetric because an equivocal trial can reset the earlier-treatment narrative while the operational CMS benefit is gradual and unlikely to offset an immediate multiple derating.
• Monitor quarterly evidence of new-site activation, procedure growth at lower-volume accounts, and gross-margin trend. If capacity expands but EW's revenue per center or margins deteriorate, it would indicate price competition or inefficient onboarding and weaken the long thesis despite higher system-wide TAVR volumes.